Rosanna K Jackson1, Martina Liebich2, Philip Berry1, Julie Errington1, Jizhong Liu3, Catriona Parker3, John Moppett4, Sujith Samarasinghe5, Rachael Hough6, Clare Rowntree7, Nick J Goulden5, Ajay Vora8, Pamela R Kearns9, Vaskar Saha10, Georg Hempel2, Julie A E Irving1, Gareth J Veal11. 1. Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, UK. 2. Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, University of Münster, Germany. 3. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK. 4. Department of Paediatric Haematology and Oncology, Bristol Royal Hospital for Children, UK. 5. Department of Haematology, Great Ormond Street Hospital for Children, London, UK. 6. University College Hospital, London, UK. 7. University Hospital of Wales, Cardiff, UK. 8. Department of Paediatric Haematology, Great Ormond Street Hospital, UK. 9. Cancer Research UK Clinical Trials Unit, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Studies, University of Birmingham, UK. 10. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK; Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India. 11. Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, UK. Electronic address: G.J.Veal@ncl.ac.uk.
Abstract
INTRODUCTION: The use of dexamethasone in acute lymphoblastic leukaemia therapy contributes to short- and long-term toxicities. The UKALL 2011 randomised trial investigated whether a more intense dexamethasone dose (10 mg/m2/d x 14d, short vs 6 mg/m2/d x 28d, standard) would lead to a more rapid cytoreduction and reduced adverse effects associated with longer durations of steroids in induction. The impact of dose and duration on dexamethasone pharmacokinetics was investigated. METHODS: Blood samples were obtained on one of the first three and last three days of induction dexamethasone dosing at time points up to 8 h after oral administration. Plasma dexamethasone levels were quantified in 1084 plasma samples obtained from 174 children and a population pharmacokinetic model developed. RESULTS: Drug exposure varied significantly between patients, with a >12-fold variation in AUC0-12h values and a marked overlap in dexamethasone exposures between dose levels. Intuitively, AUC0-12h was significantly higher with short dosing (10 mg/m2/d), but cumulative exposure was significantly higher with standard dosing over 28 days, after a higher cumulative dose. Concomitant rasburicase administration was associated with a 60% higher dexamethasone clearance. Day 8 bone marrow response was comparable between dosing arms, but those with <5% blast count exhibited a greater mean dexamethasone exposure than those with >5%. No statistical differences were observed between arms in terms of steroid-related toxicity or minimal residual disease at the end of induction. CONCLUSION: The potential significance of dexamethasone AUC0-12h on early response and higher cumulative exposure on the standard arm suggest that duration of therapy and exposure may be more important factors than absolute dose from a clinical pharmacology perspective.
RCT Entities:
INTRODUCTION: The use of dexamethasone in acute lymphoblastic leukaemia therapy contributes to short- and long-term toxicities. The UKALL 2011 randomised trial investigated whether a more intense dexamethasone dose (10 mg/m2/d x 14d, short vs 6 mg/m2/d x 28d, standard) would lead to a more rapid cytoreduction and reduced adverse effects associated with longer durations of steroids in induction. The impact of dose and duration on dexamethasone pharmacokinetics was investigated. METHODS: Blood samples were obtained on one of the first three and last three days of induction dexamethasone dosing at time points up to 8 h after oral administration. Plasma dexamethasone levels were quantified in 1084 plasma samples obtained from 174 children and a population pharmacokinetic model developed. RESULTS: Drug exposure varied significantly between patients, with a >12-fold variation in AUC0-12h values and a marked overlap in dexamethasone exposures between dose levels. Intuitively, AUC0-12h was significantly higher with short dosing (10 mg/m2/d), but cumulative exposure was significantly higher with standard dosing over 28 days, after a higher cumulative dose. Concomitant rasburicase administration was associated with a 60% higher dexamethasone clearance. Day 8 bone marrow response was comparable between dosing arms, but those with <5% blast count exhibited a greater mean dexamethasone exposure than those with >5%. No statistical differences were observed between arms in terms of steroid-related toxicity or minimal residual disease at the end of induction. CONCLUSION: The potential significance of dexamethasone AUC0-12h on early response and higher cumulative exposure on the standard arm suggest that duration of therapy and exposure may be more important factors than absolute dose from a clinical pharmacology perspective.
Authors: Andrew Reckers; Alan H B Wu; Chui Mei Ong; Monica Gandhi; John Metcalfe; Roy Gerona Journal: J Antimicrob Chemother Date: 2021-04-17 Impact factor: 5.790
Authors: Deepali Pal; Helen Blair; Jessica Parker; Sean Hockney; Melanie Beckett; Mankaran Singh; Ricky Tirtakusuma; Ryan Nelson; Hesta McNeill; Sharon H Angel; Aaron Wilson; Salem Nizami; Sirintra Nakjang; Peixun Zhou; Claire Schwab; Paul Sinclair; Lisa J Russell; Jonathan Coxhead; Christina Halsey; James M Allan; Christine J Harrison; Anthony V Moorman; Olaf Heidenreich; Josef Vormoor Journal: Cell Rep Med Date: 2022-08-16
Authors: Hui Zhang; Anthony Pak-Yin Liu; Meenakshi Devidas; Shawn Hr Lee; Xueyuan Cao; Deqing Pei; Michael Borowitz; Brent Wood; Julie M Gastier-Foster; Yunfeng Dai; Elizabeth Raetz; Eric Larsen; Naomi Winick; W Paul Bowman; Seth Karol; Wenjian Yang; Paul L Martin; William L Carroll; Ching-Hon Pui; Charles G Mullighan; William E Evans; Cheng Cheng; Stephen P Hunger; Mary V Relling; Mignon L Loh; Jun J Yang Journal: J Natl Cancer Inst Date: 2021-04-06 Impact factor: 11.816